Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Mater Private Hospital

Research site

Ireland Eccles Street, D07 WKW8 Dublin, Ireland

  • 11 trials recruiting
  • Prostate cancer · Breast cancer · Hormone receptor positive HER2 negative breast cancer
  • Adult patients

About Specializations

Mater Private Hospital in Dublin, Ireland specialises in clinical trials of conditions such as Prostate cancer, Breast cancer, Hormone receptor positive HER2 negative breast cancer, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The Oncology department at Mater Private Hospital is also exploring heart conditions, concentrating on patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. The trials seek to evaluate a novel anti‑inflammatory biologic to lower cardiovascular mortality and heart‑failure events.

  • Inflammation‑driven heart failure
  • Monthly subcutaneous biologic therapy
  • Risk reduction of cardiovascular death
  • Integration with standard heart‑failure care

With 14 investigators overseeing four active studies, the site in Dublin contributes valuable data on managing heart failure in the European research community.

Neoplasms

The oncology unit at Mater Private Hospital conducts multiple studies on prostate adenocarcinoma and various forms of breast cancer, including early‑stage ER+/HER2‑ disease. These trials aim to test new hormonal agents and targeted therapies that can delay progression, reduce metastasis, and prevent recurrence.

  • Castration‑naïve metastatic prostate cancer
  • Oral selective androgen receptor inhibitor
  • Selective estrogen receptor degraders
  • Combination endocrine therapy with CDK4/6 inhibition

Across four trials, 14 investigators are evaluating innovative treatments to improve outcomes for patients with these cancers, reinforcing the site’s role in advancing cancer care in Ireland and Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Eccles StreetD07 WKW8 DublinIreland
Open in maps ↗
Recruiting now
11 trials
Conditions studied
16

More sites in DublinIreland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Colorectal cancer metastatic

Recruiting

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Non-small cell lung cancer stage III

Recruiting

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Revolution Medicines Inc.

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Recruiting
Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer metastatic

Recruiting

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.